[1] 于庆忠,韩金祥,潘继红,等. NSCLC患者XPG、MDR-1基因单核苷酸多态性与铂类药物化疗疗效的关系[J]. 山东医药,2007,47(9):7-9. [2] Kim DH, Park JY, Sohn SK, et al. Multidmg resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myelo id leukem ia [J]. Int J Cancer, 2006, 118 (9): 2195-2201. [3] 魏嘉,刘宝瑞,王亚平,等. DNA修复基因单核苷酸多态性与铂类药物抵抗研究进展[J]. 中华肿瘤杂志,2006,28(3):161-163. [4] 江艺,邱希辉,林丹霞,等. 铂类联合多西他赛一线治疗晚期食管癌[J]. 中国临床药理学与治疗学,2009,14(12):1395-1399. [5] Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer [J]. Anticancer Res, 2001, 21: 3075-3079. [6] 袁芃,缪小平,张雪梅,等. DNA损伤修复基因XRCC1和XPD遗传多态与晚期非小细胞肺癌对铂类药物的敏感性[J]. 中华肿瘤杂志,2006,28(3):196-199. [7] 邱立新,钱晓萍,刘宝瑞,等. XRCC1基因多态性与晚期非小细胞肺癌铂类药物化疗敏感性的关系[J]. 现代肿瘤医学,2009,17(2):263-265. [8] 王中华,缪小平,谭 文,等. XRCC1单核苷酸多态与晚期非小细胞肺癌对铂类药物敏感性的相关性[J]. 癌症,2004,23(8):865-868. [9] 戴穹,杨志惠. DNA修复基因XRCC3 Thr241Met多态性在四川汉族人群的分布[J]. 泸州医学院学报,2007,30(1):11-14. [10] Monzo M, Brunet S, Urbano-Isp izua A, et al. Genomic polymorphisms provide prognostic information in intermediaterisk acute myeloblastic leukemia [J]. Blood, 2006, 107 (12):4871-4879. [11] 袁芃,缪小平,张雪梅,等. XPC和XPD基因遗传多态与晚期非小细胞肺癌对铂类药的敏感性[J]. 中华医学杂志,2005,85(14):972-975. [12] 陈健,何义富,胡冰. 核苷酸切除修复基因多态性和铂类药物耐药性关系研究进展[J]. 现代肿瘤医学,2009,17(4):763-766. [13] Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy [J]. J Clin Oncol, 2004, 22 (13):2594-2601. [14] 丁忠海. DNA修复基因XPD751基因多态性与肺癌化疗敏感性的关系研究[D].南京医科大学学位论文,2008.6 [15] Jeon HS, Kim KM, Park SH, et al. Relationship between XPG codon 1104 polymorphism and risk of primary lung cancer[J]. Carcinogenesis, 2003, 24: 1677-1681. [16] Vila JM, Moreno I, MonzoM, et al. XPD, XPA, ERCC1 and XPG/ERCC5 single nucleotide polymorphisms ( SNPs) in oxaliplatin-treated colorectal cancer (CRC) [J]. Clin Oncol, 2004, 22: 3677. [17] Bellmunt J, Paz Ares L, Cuello M, et al . Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy [J].Ann Oncol, 2007, 18 (3) :522-528. [18] 周伟华,邓觐云. ERCC1及其基因多态性与铂类耐药的相关性[J]. 江西医药,2009,44(2):179-182. [19] Steffensen KD, Waldstrom M, Jeppesen U,et al. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 poly-morphism in ovarian cancer[J]. Int J Gynecol Cancer,2008,18(4):702. [20] 袁芃,缪小平,张雪梅,等. 晚期非小细胞肺癌对铂类药物的化疗敏感性与p53和p73基因多态的关系[J]. 中华肿瘤杂志,2006,28(2):107-110. [21] 茆勇,黄朝晖,华东,等. 谷胱甘肽S转移酶基因多态性与NSCLC化疗疗效的关系[J]. 山东医药,2007,47(36):68-69. |